DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Poland ONLY.

Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)

NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, and as a booster dose approximately 6 months after the second dose in individuals 18 years of age and older.

Report an Adverse Event (AE)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Poland.

Departament Monitorowania Niepożądanych Działań Produktów Leczniczych Urzędu Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych
Al. Jerozolimskie 181C
02-222 Warszawa, Polska
Tel.: +48 22 49 21 301
Faks: +48 22 49 21 309
Strona internetowa: www.mz.ezdrowie.gov.pl

Contact Us

Tel: +48 22 104 74 91
09:00 - 17:00
Monday - Friday